Canada
· Delayed Price · Currency is CAD BioNxt Solutions Statistics
Total Valuation
BioNxt Solutions has a market cap or net worth of CAD 29.48 million. The enterprise value is 34.54 million.
| Market Cap | 29.48M |
| Enterprise Value | 34.54M |
Important Dates
The next estimated earnings date is Monday, November 25, 2024.
| Earnings Date | Nov 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNxt Solutions has 113.40 million shares outstanding. The number of shares has increased by 15.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 113.40M |
| Shares Change (YoY) | +15.13% |
| Shares Change (QoQ) | +0.70% |
| Owned by Insiders (%) | 6.03% |
| Owned by Institutions (%) | n/a |
| Float | 106.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.38 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.27 |
Financial Position
The company has a current ratio of 0.09
| Current Ratio | 0.09 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.28 |
| Interest Coverage | -5.10 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -228.25% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.85% in the last 52 weeks. The beta is 0.66, so BioNxt Solutions's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -53.85% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 0.35 |
| Relative Strength Index (RSI) | 57.02 |
| Average Volume (20 Days) | 65,683 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNxt Solutions had revenue of CAD 30,637 and -6.42 million in losses. Loss per share was -0.06.
| Revenue | 30,637 |
| Gross Profit | 30,637 |
| Operating Income | -5.11M |
| Pretax Income | -6.42M |
| Net Income | -6.42M |
| EBITDA | -5.00M |
| EBIT | -5.11M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 309,624 in cash and 5.36 million in debt, giving a net cash position of -5.05 million or -0.04 per share.
| Cash & Cash Equivalents | 309,624 |
| Total Debt | 5.36M |
| Net Cash | -5.05M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -6.13M |
| Book Value Per Share | -0.05 |
| Working Capital | -6.58M |
Cash Flow
In the last 12 months, operating cash flow was -4.09 million and capital expenditures -84,319, giving a free cash flow of -4.18 million.
| Operating Cash Flow | -4.09M |
| Capital Expenditures | -84,319 |
| Free Cash Flow | -4.18M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -16,678.12% |
| Pretax Margin | -20,944.27% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -13,636.21% |
Dividends & Yields
BioNxt Solutions does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.13% |
| Shareholder Yield | -15.13% |
| Earnings Yield | -23.26% |
| FCF Yield | -14.17% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNxt Solutions has an Altman Z-Score of -100.27. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -100.27 |
| Piotroski F-Score | n/a |